Watch for the patent infringement lawsuit to be filed within the 45-day window (by mid-November 2026). The 30-month stay would push earliest generic entry to at least April 2029, but a loss in court or settlement could accelerate competition. Monitor TONMYA sales trajectory and any subsequent Paragraph IV filings from other generic manufacturers.
Price Chart
Executive Summary
Tonix received a Paragraph IV ANDA notice from Dr. Reddy's Laboratories seeking FDA approval for a generic version of its drug TONMYA (cyclobenzaprine HCl sublingual tablets, 2.8 mg) before the expiration of four Orange-Book-listed patents. The company intends to sue within 45 days, which would trigger an automatic 30-month stay on FDA approval, but the outcome of any litigation is uncertain and generic competition poses a material threat to TONMYA's revenue stream.
Key Facts
- Received Paragraph IV ANDA notice from Dr. Reddy's Laboratories for a generic version of TONMYA (cyclobenzaprine HCl sublingual tablets, 2.8 mg) on October 1, 2026.
- The Paragraph IV certification challenges four Orange-Book-listed patents: U.S. Patent Nos. 9,636,408; 9,956,188; 10,117,936; and 10,864,175.
- Filing a patent infringement lawsuit within 45 days of the notice automatically stays FDA approval of the ANDA for up to 30 months from the notice date.
- Company intends to vigorously enforce its intellectual property rights but cannot predict the outcome of litigation.
- No financial figures (revenue, market size, litigation costs) were disclosed in the filing.
Financial Impact
No financial figures disclosed; TONMYA is the company's commercial product and generic entry would materially reduce its revenue stream.
Risk Factors
- One or more patents could be found invalid, unenforceable, or not infringed, allowing FDA approval of the ANDA before patent expiration.
- Litigation costs and management distraction could strain a small-cap biotech's resources.
- Other generic applicants may file additional Paragraph IV ANDAs, increasing competitive pressure.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-045603 |
| Document: 0001493152-26-045603-index-headers.html | 0001493152-26-045603 |
| Document: 0001493152-26-045603-index.html | 0001493152-26-045603 |
| Document: 0001493152-26-045603.txt | 0001493152-26-045603 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | Press Release | $5.73 | awaiting T+20 | — | $5.30 (−7.50%) |
Oct 15, 2026 11d ago | 8-K | $6.42 | awaiting T+20 | — | $5.30 (−17.45%) |
Oct 2, 2026 24d ago | 8-K | $8.07 | awaiting T+20 | — | $5.30 (+34.32%) |
Sep 22, 2026 4w ago | 8-K | $10.59 $5.78 | ▼ −45.42% | ▼ −44.86% | $5.30 (−49.95%) |
Sep 8, 2026 6w ago | 8-K | $13.16 $7.70 | ▼ −41.49% | ▼ −43.46% | $5.30 (−59.73%) |
Aug 10, 2026 11w ago | 8-K | $12.59 $13.16 | ▲ +4.53% | ▲ +5.44% | $5.30 (−57.90%) |
Aug 10, 2026 11w ago | Press Release | $12.59 $13.16 | ▲ +4.53% | ▲ +5.44% | $5.30 (−57.90%) |
Aug 3, 2026 12w ago | 8-K | $10.67 $14.10 | ▲ +32.15% | ▲ +30.91% | $5.30 (−50.33%) |
Jul 27, 2026 13w ago | Press Release | $10.37 $12.45 | ▲ +20.06% | ▲ +16.76% | $5.30 (−48.89%) |
Jul 13, 2026 15w ago | 8-K | $11.71 $12.59 | ▲ +7.56% | ▲ +4.38% | $5.30 (−54.72%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers